• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对存在总体时间因素的前列腺癌的阿尔法/贝塔比值的荟萃分析:坏消息,好消息,还是没有消息?

Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?

机构信息

Department of Radiation Oncology, Rigshospitalet, University of Copenhagen, Denmark.

出版信息

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):89-94. doi: 10.1016/j.ijrobp.2012.03.004. Epub 2012 May 30.

DOI:10.1016/j.ijrobp.2012.03.004
PMID:22652106
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3556929/
Abstract

PURPOSE

To present a novel method for meta-analysis of the fractionation sensitivity of tumors as applied to prostate cancer in the presence of an overall time factor.

METHODS AND MATERIALS

A systematic search for radiation dose-fractionation trials in prostate cancer was performed using PubMed and by manual search. Published trials comparing standard fractionated external beam radiation therapy with alternative fractionation were eligible. For each trial the α/β ratio and its 95% confidence interval (CI) were extracted, and the data were synthesized with each study weighted by the inverse variance. An overall time factor was included in the analysis, and its influence on α/β was investigated.

RESULTS

Five studies involving 1965 patients were included in the meta-analysis of α/β. The synthesized α/β assuming no effect of overall treatment time was -0.07 Gy (95% CI -0.73-0.59), which was increased to 0.47 Gy (95% CI -0.55-1.50) if a single highly weighted study was excluded. In a separate analysis, 2 studies based on 10,808 patients in total allowed extraction of a synthesized estimate of a time factor of 0.31 Gy/d (95% CI 0.20-0.42). The time factor increased the α/β estimate to 0.58 Gy (95% CI -0.53-1.69)/1.93 Gy (95% CI -0.27-4.14) with/without the heavily weighted study. An analysis of the uncertainty of the α/β estimate showed a loss of information when the hypofractionated arm was underdosed compared with the normo-fractionated arm.

CONCLUSIONS

The current external beam fractionation studies are consistent with a very low α/β ratio for prostate cancer, although the CIs include α/β ratios up to 4.14 Gy in the presence of a time factor. Details of the dose fractionation in the 2 trial arms have critical influence on the information that can be extracted from a study. Studies with unfortunate designs will supply little or no information about α/β regardless of the number of subjects enrolled.

摘要

目的

提出一种新的方法,用于分析存在总体时间因素时肿瘤的分割敏感性,以前列腺癌为例。

方法和材料

使用 PubMed 和手动搜索对前列腺癌的放射剂量分割试验进行了系统搜索。合格的试验比较了标准分割外照射与替代分割。从每个试验中提取 α/β 比值及其 95%置信区间(CI),并通过每个研究的逆方差加权对数据进行综合。分析中包含了一个整体时间因素,并研究了其对 α/β 的影响。

结果

共有 5 项涉及 1965 例患者的研究被纳入α/β 的荟萃分析。假设没有总治疗时间影响的综合α/β 为-0.07 Gy(95%CI-0.73-0.59),如果排除一个高度加权的研究,则增加至 0.47 Gy(95%CI-0.55-1.50)。在单独的分析中,共有 2 项基于总共 10808 例患者的研究允许提取一个综合的时间因素估计值,为 0.31 Gy/d(95%CI0.20-0.42)。时间因素使α/β 估计值增加至 0.58 Gy(95%CI-0.53-1.69)/1.93 Gy(95%CI-0.27-4.14),同时包括/不包括高度加权的研究。对α/β 估计值不确定性的分析表明,当低分割臂与常规分割臂相比剂量不足时,信息会丢失。

结论

目前的外照射分割研究与前列腺癌的非常低的α/β比值一致,尽管在存在时间因素的情况下,CI 包括高达 4.14 Gy 的α/β 比值。2 个试验臂的剂量分割细节对从研究中提取信息具有关键影响。无论纳入的受试者数量多少,设计不佳的研究都将提供很少或没有关于α/β 的信息。

相似文献

1
Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?针对存在总体时间因素的前列腺癌的阿尔法/贝塔比值的荟萃分析:坏消息,好消息,还是没有消息?
Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):89-94. doi: 10.1016/j.ijrobp.2012.03.004. Epub 2012 May 30.
2
Dose Response and Fractionation Sensitivity of Prostate Cancer After External Beam Radiation Therapy: A Meta-analysis of Randomized Trials.外照射放疗后前列腺癌的剂量反应和分割敏感性:随机试验的荟萃分析。
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):858-865. doi: 10.1016/j.ijrobp.2017.12.011. Epub 2017 Dec 15.
3
Hypofractionation for clinically localized prostate cancer.临床局限性前列腺癌的大分割放疗
Cochrane Database Syst Rev. 2019 Sep 3;9(9):CD011462. doi: 10.1002/14651858.CD011462.pub2.
4
Later outcomes and alpha/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer.局部前列腺癌三维适形低分割与常规分割放疗的后期结果和α/β比值估计。
Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1200-7. doi: 10.1016/j.ijrobp.2010.12.040. Epub 2011 Apr 7.
5
Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy.从 7 个国际机构数据集的 5969 名患者的放射治疗结果推断出前列腺癌的剂量分割敏感性:α/β = 1.4(0.9-2.2)Gy。
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):e17-24. doi: 10.1016/j.ijrobp.2010.10.075. Epub 2011 Feb 15.
6
Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.高剂量率(HDR)近距离放射治疗联合低分割外照射放疗治疗局限性前列腺癌后的急性泌尿生殖系统毒性:HDR近距离放射治疗中尿道剂量与急性泌尿生殖系统毒性严重程度之间的相关性
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):463-71. doi: 10.1016/j.ijrobp.2004.11.041.
7
Is alpha/beta for prostate tumors really low?前列腺肿瘤的α/β值真的很低吗?
Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):1021-31. doi: 10.1016/s0360-3016(01)01607-8.
8
Comparison of in vitro and in vivo alpha/beta ratios for prostate cancer.前列腺癌体外与体内α/β比值的比较
Phys Med Biol. 2004 Oct 7;49(19):4477-91. doi: 10.1088/0031-9155/49/19/003.
9
Estimation of a self-consistent set of radiobiological parameters from hypofractionated versus standard radiation therapy of prostate cancer.从前列腺癌的超分割与标准放射治疗中估计一组自洽的放射生物学参数。
Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):e231-7. doi: 10.1016/j.ijrobp.2012.11.033. Epub 2013 Jan 17.
10
Hypofractionated Versus Standard Fractionated Proton-beam Therapy for Low-risk Prostate Cancer: Interim Results of a Randomized Trial PCG GU 002.低危前列腺癌的大分割质子束疗法与标准分割质子束疗法对比:随机试验PCG GU 002的中期结果
Am J Clin Oncol. 2018 Feb;41(2):115-120. doi: 10.1097/COC.0000000000000241.

引用本文的文献

1
Comprehensive one-day management of prostate cancer patients: PRO-FAST single-fraction ablative, urethral-sparing, HDR-like, robotic SBRT.前列腺癌患者的单日综合管理:PRO-FAST单次消融、保留尿道、类似高剂量率近距离放疗的机器人立体定向体部放疗
Radiat Oncol. 2025 Aug 27;20(1):134. doi: 10.1186/s13014-025-02713-9.
2
Predictive Factors for Gastrointestinal and Genitourinary Toxicities in Prostate Cancer External Beam Radiotherapy: A Scoping Review.前列腺癌外照射放疗中胃肠道和泌尿生殖系统毒性的预测因素:一项范围综述
Diagnostics (Basel). 2025 May 26;15(11):1331. doi: 10.3390/diagnostics15111331.
3
Biochemical failure-free survival of F-rhPSMA-7 and F-flotufolastat PET-guided salvage radiotherapy for patients with recurrent prostate cancer.

本文引用的文献

1
Later outcomes and alpha/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer.局部前列腺癌三维适形低分割与常规分割放疗的后期结果和α/β比值估计。
Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1200-7. doi: 10.1016/j.ijrobp.2010.12.040. Epub 2011 Apr 7.
2
Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy.从 7 个国际机构数据集的 5969 名患者的放射治疗结果推断出前列腺癌的剂量分割敏感性:α/β = 1.4(0.9-2.2)Gy。
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):e17-24. doi: 10.1016/j.ijrobp.2010.10.075. Epub 2011 Feb 15.
3
F-rhPSMA-7和F-氟托泊肟PET引导下的挽救性放射治疗对复发性前列腺癌患者的无生化失败生存期
Sci Rep. 2025 Jan 17;15(1):2234. doi: 10.1038/s41598-024-83074-3.
4
Evidences on the Use of Hypofractionation in Postoperative/Salvage Radiotherapy for Prostate Cancer: Systematic Review of the Literature and Recent Developments.前列腺癌术后/挽救性放疗中使用大分割放疗的证据:文献系统综述与最新进展
Cancers (Basel). 2024 Dec 18;16(24):4227. doi: 10.3390/cancers16244227.
5
Carbon ion radiation therapy in prostate cancer: The importance of dosage.前列腺癌的碳离子放射治疗:剂量的重要性。
World J Radiol. 2024 Nov 28;16(11):696-699. doi: 10.4329/wjr.v16.i11.696.
6
Radiation Oncologists' Perspectives on Oligometastatic Prostate Cancer: A Survey from Korean Oligometastasis Working Group.放疗科医生对寡转移前列腺癌的观点:来自韩国寡转移工作组的一项调查。
Curr Oncol. 2024 Jun 3;31(6):3239-3251. doi: 10.3390/curroncol31060245.
7
Differential outcomes of re-stratified high-risk prostate cancer patients treated with external beam radiation therapy plus high-dose-rate brachytherapy boost.接受外照射放疗加近距离高剂量率后装治疗的重新分层高危前列腺癌患者的不同结局
J Contemp Brachytherapy. 2024 Apr;16(2):103-110. doi: 10.5114/jcb.2024.139277. Epub 2024 Apr 30.
8
Simulating an intra-fraction adaptive workflow to enable PTV margin reduction in MRIgART volumetric modulated arc therapy for prostate SBRT.模拟分次内自适应工作流程,以在前列腺立体定向体部放疗的磁共振引导容积调强弧形治疗中减少计划靶区(PTV)边界。
Front Oncol. 2024 Jan 8;13:1325105. doi: 10.3389/fonc.2023.1325105. eCollection 2023.
9
Long-term findings of rectal endoscopy and rectal bleeding after moderately hypofractionated, intensity-modulated radiotherapy for prostate cancer.中低度分割调强放疗前列腺癌后直肠内镜和直肠出血的长期结果。
Sci Rep. 2023 Dec 13;13(1):22099. doi: 10.1038/s41598-023-43202-x.
10
An optimal method of hydrogel spacer insertion for stereotactic body radiation therapy of prostate cancer.一种用于前列腺癌立体定向体部放射治疗的水凝胶间隔物插入的优化方法。
Jpn J Radiol. 2024 Apr;42(4):406-414. doi: 10.1007/s11604-023-01506-y. Epub 2023 Nov 7.
Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial.前列腺癌的低分割与常规分割放疗比较:III 期随机试验的最终结果。
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1271-8. doi: 10.1016/j.ijrobp.2010.07.1984. Epub 2010 Oct 8.
4
Fractionation in prostate cancer--is it time after all?前列腺癌的分割放疗——终究到时候了吗?
Radiother Oncol. 2010 Jul;96(1):1-5. doi: 10.1016/j.radonc.2010.06.001. Epub 2010 Jun 19.
5
The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995.总体治疗时间在前列腺癌放射治疗结果中的作用:1987 年至 1995 年期间治疗的 4839 名男性患者生化失败的分析。
Radiother Oncol. 2010 Jul;96(1):6-12. doi: 10.1016/j.radonc.2010.03.020. Epub 2010 Apr 17.
6
Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics.采用治疗后 PSA 动力学重复测量模型证实单纯外照射放疗治疗前列腺癌的低α/β 比值。
Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):195-201. doi: 10.1016/j.ijrobp.2009.10.008. Epub 2010 Apr 8.
7
A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer.前瞻性 III 期随机试验:高危前列腺癌患者的低分割放疗与常规分割放疗比较。
Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):11-8. doi: 10.1016/j.ijrobp.2009.07.1691. Epub 2010 Jan 4.
8
A new method for synthesizing radiation dose-response data from multiple trials applied to prostate cancer.一种综合来自多个试验的辐射剂量-反应数据的新方法,应用于前列腺癌。
Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1066-71. doi: 10.1016/j.ijrobp.2009.06.013. Epub 2009 Oct 31.
9
Does treatment duration affect outcome after radiotherapy for prostate cancer?前列腺癌放疗后的治疗持续时间会影响治疗结果吗?
Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1402-7. doi: 10.1016/j.ijrobp.2008.03.011. Epub 2008 May 9.
10
Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer--the CHHiP trial.剂量、分割方式与技术问题:前列腺癌超分割放疗试验的测试要素——CHHiP试验
Clin Oncol (R Coll Radiol). 2008 Feb;20(1):12-4. doi: 10.1016/j.clon.2007.10.008. Epub 2007 Nov 26.